Class summary at a glance.

Every drug in the Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $4.3Mcombined across class
Total Rx claims: 23389 unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Ganaxolone

Brand: ZTALMY · 167 Part D claims (CY24) · 24 beneficiaries · First FDA approval: 2022-06-06

Brand-only (no generics) 324 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $3.3M

Class share

75%

of class CY24 spend

View profile →

Zuranolone

Brand: ZURZUVAE · 66 Part D claims (CY24) · 65 beneficiaries · First FDA approval: 2023-10-31

Brand-only (no generics) 843 plans require PA